search
Back to results

Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens

Primary Purpose

Morbid Obesity, Postoperative Pain, Postoperative Bowel Function

Status
Completed
Phase
Phase 2
Locations
Greece
Study Type
Interventional
Intervention
GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE
GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE
GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE
GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE
GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Sponsored by
University of Patras
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Morbid Obesity focused on measuring open gastric by-pass, super morbidly obese patients, postoperative thoracic epidural analgesia, different drug regimens (morphine and levobupivacaine), Lung function tests, Postoperative Bowel recovery, Postoperative Ambulation

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Body mass index (BMI) > 50
  • Age < 50
  • Patients written consent to participate in the study

Exclusion Criteria:

  • Cardiovascular disease (valvular and ischemic heart disease)
  • Patients refusal to participate in the study
  • Contraindication to epidural catheter placement (e.g anticoagulation, anti- platelets medication)
  • Active psychiatric disease requiring treatment
  • Redo surgery

Sites / Locations

  • University of Patras, Department of Anesthesiology and Critical Care Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE

GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE

GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE

GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE

GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE

GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE

Arm Description

Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h

Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h

Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h

Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h

Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h

Outcomes

Primary Outcome Measures

Change From Baseline in Pain Scores (Visual Analogue Scale)
Pain scores at rest and on cough using a 10cm Visual Analogue Scale(0=no pain, 10=worst possible pain) were assessed up to 48h postoperatively.

Secondary Outcome Measures

Time to Postoperative Bowel Recovery
Time to postoperative recovery of bowel function assessed by first flatus or stool, noticed by the patient
Time to First Postoperative Ambulation
Time to being able to walk without assistance within the room or outside the room
Consumption of Levobupivacaine at 24h and 48 h Postoperatively
Cumulative consumption of levobupivacaine administered via patients controlled epidural analgesia pump( PCEA) at 24h and 48 h postoperatively
Cumulative Consumption of Epidural Morphine at 24h and 48h Postoperatively
Cumulative consumption of epidural morphine administered as loading dose, intraoperatively, of 1mg(groups B and E)or 2mg (groups C and F) and as continuous infusion of 0,2mg/h ( all groups) at 24h and 48h postoperatively.All participants in each Group received the same dose of epidural morphine, as no participant missed a scheduled dose.
Change From Baseline of Spirometric Values
Preoperatively, after a detailed demonstration, baseline spirometry measurements of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and peak expiratory flow rate (PEFR) were measured, using a bedside spirometer (PowerCubeΤΜ, Ganshorn Medizin Electronic, Germany), on-line connected to a PC. Spirometry was standardized with each patient in a 30o head-up position and it was performed at least three times and the best measurement was recorded, according to the criteria of the European Respiratory Society .Postoperatively, spirometric values (FVC= Forced Vital Capacity, FEV1=Forced Expiratory Volume at 1 sec , PEFR= Peak Expiratory Flow Rate)were recorded at 12, 24, 36, 48, 72, 144 hours . Data are expressed as percentage of preoperative values, which are 100%.

Full Information

First Posted
November 22, 2010
Last Updated
June 18, 2013
Sponsor
University of Patras
search

1. Study Identification

Unique Protocol Identification Number
NCT01249872
Brief Title
Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens
Official Title
Postoperative Thoracic Epidural Analgesia in Super Obese Patients (~BMI 60 kg m-2) Undergoing Open Weight Loss Surgery :Does the Addition of Morphine to 0.1% and 0.2% Levobupivacaine Affect Postoperative Pain Relief, Perioperative Lung Function, Return of Normal Gastrointestinal Mobility and Ambulation?
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
September 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Patras

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Adequate postoperative analgesia can facilitate recovery following gastric bypass surgery for morbid obesity. The efficacy and safety of intravenous patient - controlled analgesia has been studied, but up to date no data are available concerning the use of thoracic epidural patient-controlled analgesia regarding the use of levobupivacaine combined with morphine in morbidly obese patients. The investigators' aim in this prospective, randomized, double-blinded study was to compare the analgesic effectiveness, the dose requirements and side effects of thoracic epidural patient controlled analgesia 0.1% and 0.2% levobupivacaine combined with a continuous epidural administration of morphine, with or without a loading dose, after open gastric bypass for morbid obesity.
Detailed Description
Morbidly obese patients (BMI > 50 kg/m2) planned to undergo open variant of biliopancreatic diversion with Roux-en-Y gastric bypass (BPD-RYGBP) received standardized general anesthesia (intravenous propofol combined with remifentanyl and muscle relaxation). Preoperatively, in all patients an epidural catheter in the thoracic spine level will be placed between T5 and T8 interspace. All patients will be randomly allocated to six groups: Group A patients will receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation patient controlled epidural anesthesia (PCEA)with 0.1% levobupivacaine (5ml, lockout interval 10min) , combined with a continuous epidural infusion of morphine 0.2 mg/h will be administered, Group B patients will receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery) and postoperatively the same levobupivacaine and morphine regimen as Group A, Group C patients will receive an epidural bolus dose 2 mg of morphine intra-operatively and thereafter the same levobupivacaine and morphine regimen as Group A. Group D patients will receive intra-operatively an epidural bolus dose of 2 ml of normal saline. Postoperatively, the patients will receive PCEA in a dose of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h, Group E patients will receive intra-operatively an epidural bolus dose of 1mg of morphine intra-operatively and postoperatively the same regimen as Group D. Group F patients will receive intra-operatively an epidural bolus dose of 2 mg of morphine intra-operatively and thereafter the same regimen as Group D. Pain assessment will be performed using visual analogue scale (VAS, 10cm scale) at rest, at mobilization and at cough. Furthermore, total local anesthetic and morphine consumption, side effects on cardiovascular, respiratory and gastrointestinal systems, including blood pressure,blood gases, spirometric values Forced Expiratory Volume at 1 sec (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow Rate (PEFR), incidents of postoperative nausea and vomiting (PONV), pruritus, time to first flatus, postoperative ambulation will be recorded for up to 6 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity, Postoperative Pain, Postoperative Bowel Function, Postoperative Ambulation
Keywords
open gastric by-pass, super morbidly obese patients, postoperative thoracic epidural analgesia, different drug regimens (morphine and levobupivacaine), Lung function tests, Postoperative Bowel recovery, Postoperative Ambulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Arm Title
GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
Arm Title
GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
Arm Title
GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
Arm Title
GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
Arm Title
GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Arm Type
Active Comparator
Arm Description
Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
Intervention Type
Drug
Intervention Name(s)
GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Intervention Type
Drug
Intervention Name(s)
GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Intervention Type
Drug
Intervention Name(s)
GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Intervention Type
Drug
Intervention Name(s)
GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Intervention Type
Drug
Intervention Name(s)
GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Intervention Type
Drug
Intervention Name(s)
GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Other Intervention Name(s)
Morfina cloridrato 10 mg /ml - Morphine, Chirocaine 5 mg/ml - Levobupivacaine
Intervention Description
Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Primary Outcome Measure Information:
Title
Change From Baseline in Pain Scores (Visual Analogue Scale)
Description
Pain scores at rest and on cough using a 10cm Visual Analogue Scale(0=no pain, 10=worst possible pain) were assessed up to 48h postoperatively.
Time Frame
up to 48 h postoperatively
Secondary Outcome Measure Information:
Title
Time to Postoperative Bowel Recovery
Description
Time to postoperative recovery of bowel function assessed by first flatus or stool, noticed by the patient
Time Frame
up to 6 days
Title
Time to First Postoperative Ambulation
Description
Time to being able to walk without assistance within the room or outside the room
Time Frame
up to 6 days
Title
Consumption of Levobupivacaine at 24h and 48 h Postoperatively
Description
Cumulative consumption of levobupivacaine administered via patients controlled epidural analgesia pump( PCEA) at 24h and 48 h postoperatively
Time Frame
up to 48 hours postoperatively
Title
Cumulative Consumption of Epidural Morphine at 24h and 48h Postoperatively
Description
Cumulative consumption of epidural morphine administered as loading dose, intraoperatively, of 1mg(groups B and E)or 2mg (groups C and F) and as continuous infusion of 0,2mg/h ( all groups) at 24h and 48h postoperatively.All participants in each Group received the same dose of epidural morphine, as no participant missed a scheduled dose.
Time Frame
up to 48 hours postoperatively
Title
Change From Baseline of Spirometric Values
Description
Preoperatively, after a detailed demonstration, baseline spirometry measurements of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and peak expiratory flow rate (PEFR) were measured, using a bedside spirometer (PowerCubeΤΜ, Ganshorn Medizin Electronic, Germany), on-line connected to a PC. Spirometry was standardized with each patient in a 30o head-up position and it was performed at least three times and the best measurement was recorded, according to the criteria of the European Respiratory Society .Postoperatively, spirometric values (FVC= Forced Vital Capacity, FEV1=Forced Expiratory Volume at 1 sec , PEFR= Peak Expiratory Flow Rate)were recorded at 12, 24, 36, 48, 72, 144 hours . Data are expressed as percentage of preoperative values, which are 100%.
Time Frame
up to 6th day postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Body mass index (BMI) > 50 Age < 50 Patients written consent to participate in the study Exclusion Criteria: Cardiovascular disease (valvular and ischemic heart disease) Patients refusal to participate in the study Contraindication to epidural catheter placement (e.g anticoagulation, anti- platelets medication) Active psychiatric disease requiring treatment Redo surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
KRITON S FILOS, MD, PhD, PROFESSOR
Organizational Affiliation
Department of Anesthesiology and Critical Care
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
ATHINA SIAMPALIOTH, MD
Organizational Affiliation
University Hospital of Patras
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
ANASTASIA ZOTOU, MD
Organizational Affiliation
University Hospital of Patras
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Patras, Department of Anesthesiology and Critical Care Medicine
City
Patras
State/Province
Achaia
ZIP/Postal Code
26500
Country
Greece

12. IPD Sharing Statement

Learn more about this trial

Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens

We'll reach out to this number within 24 hrs